CA1122503A - Immunochemical testing using tagged reagents - Google Patents

Immunochemical testing using tagged reagents

Info

Publication number
CA1122503A
CA1122503A CA315,018A CA315018A CA1122503A CA 1122503 A CA1122503 A CA 1122503A CA 315018 A CA315018 A CA 315018A CA 1122503 A CA1122503 A CA 1122503A
Authority
CA
Canada
Prior art keywords
reagent
reactance
immune
receptor
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA315,018A
Other languages
French (fr)
Inventor
Richard C. Ebersole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/942,261 external-priority patent/US4219335A/en
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Application granted granted Critical
Publication of CA1122503A publication Critical patent/CA1122503A/en
Expired legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE
The presence of a particular immunochemically reactive substance in a biological fluid can be determined using immune reagents tagged with particules which have characteristics capable of affecting electrical reactance.

Description

Z~;03 B~CKGROUND OF THE INVENTION
This invention relates to a method for determin-ing the presence of selected immunochemically responsive substances such as antibodies or antigens in body fluids.
These selected substances will be referred to hereinafter as analytes.
The determination of such analytes provides much useful medical information. For example, pregnancy testing, syphillis testing and blood factor testing are all now done by conventional immunochemical methods.
Most of these methods involve a visual inspection for the formation of precipitated or agglutinated antigen-antibody complexes. These methods sometimes require several replications at different reagent ratios to insure accuracy and also require an individual visual inspection for each test result. Use has also been made of radioactive and fluorescent tags to avoid the subjective visual determination. However, these methods sometimes have problems either in the use of expensive or transient tags, or in sensitivity or in safety and handling of radioactive materials. The method of this invention uses immune reagents tagged with particles such as magnetic materials which are safe to handle and which can be detected readily with highly sensitive and readily available electronic equipment. This method is readily adaptable to automated or semi-automated operation.

~2~:50:~

The use of magnetic particles in serological testing is known, but prior to this invention the magnetic particles have been used only to remove or sequester various components from a liquid sample. For example, U.S.
4,018,886 and U.S. 3,970,518, teach the use of magnetically active particles to collect selected proteins, followed by cleaving the proteins from the magnetic particles and a visual examination for precipitated proteins. Hersh et al., U.S. 3,333,997, teaches the use of magnetic particles to concentrate radioactive tags on a test substance.
None of the references teach the use of magnetic detection to obtain the desired result.
SUMMARY OF THE INVENTION
The presence or absence in a body fluid of an analyte, such as a specific antigen or antibody, can be determined by depositing a sample of the body fluid on a surface coated with a receptor reagent specifically ~eactive with the analyte. If the analyte is present, it will form a complex with the receptor reagent. The surface is then contacted with an immune reagent comprising an immune component which is specifically reactive with either the receptor reagent or with a complex of the receptor reagent and the analyte. The immune reagent also comprises particles which have characteristics capable of affecting electrical reactance. That is, they are minute fragments which alter the permittivity, conductivity or magnetic permeability of the surface. These particles will be referred to in this case as reactance tags. ~etal or metal oxide particles are preferred, and magnetically active particles are more preferred. The immune reagent is generally applied to the 1~2Z503 surface as a liquid suspension. Unreacted immune reagent is then removed from the surface and the surface is examined for changes in dielectric constant, conductivity or magnetic permeabiLity. In a direct test, the immune reagent is reactive with the receptor reagent-analyte complex and if the reactance tags are found to be attached to the surface, the presence of the analyte in the body fluid is indicated.
Similarly, in an indirect test, the immune reagent is reac-tive with the receptor reagent but not with the receptor reagent analyte complex. If no reactance tags are detected on the surface, the presence of the analyte in the body fluid is indicated. In a competitive test th~ body 1uid and immune reagent are deposited on the surface simultan-eously. The amount of reactance tags on the surface is a measure of the amount of analyte in the body fluid. This system may be used manually, but it is readily adaptable to automated operation.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a drawing of a test card useful in this invention. Figure 2 is a schematic representation of the reactions involved in this invention.
DETAILED DESCRIPTION OF THE INVENTION
Conventional means can be used to detect the presence of the reactance tags on the test sur~ace. For example, if the reactance tags affect the dielectric properties of the surface, a capacitance measurement will reveal whether the particles are present. In another example, if the particles ar~ magneti~, magnetic pick up heads such as those found in standard tape recording equip-ment may be used. Capacitive, conductive and magnetic ;

~12Z503 permeability measurements that do not require direct contactwith the test surface are preferred, but measurements using direct contact between the surface and the detector are not excluded. In order for the presence of the particles to be detected, it is preferable that the test surface be inert with respect to the property to be measured. However, it is possible to arrange the receptor reagent on the surface in bands or to induce a periodic magnetization on the surface as that produced by a magnetic tape recording system and then 'o move the surface at a particular rate past a detec-tor which will monitor frequency. The detected frequency will be a function o~ the arrangement of the bands of receptor reagent or induced periodic magnetization and the rate of mo~ement of the surface. Thus, the test surface itself need not be entirely free from electrical reactance to be considered inert for the purposes of this invention.
In a preferred system for detecting the presence of magnetic tag, the test surface is adjacent to a reference surface coated with magnetic particles. Following the immune reac-tions, both the test surface and the reference surface canbe magnetized in~a periodic fashion. The detector circuit can be made to detect only the portion of the signal from the test sur~ace which is in place with the signal from the reference surface. This arrangement decreases the effects of system noise and provides increased sensitivity.
The test surface must also be capable of bonding with the receptor reagent and non-interfering with the test result. The surface can be flat or it can have depressions or dimples in which each test is conducted. While many materials are suitable test surfaces, plastic cards or .ZZ~Q3 tapes are preferred. The test surface on which receptor reagent is bonded may be within enclosed plastic packs or pouches. These packs can also contain the immune reagents in a separate area designed for addition to the test surface following sample addition.
The presence of a change in electrical reactance such as magnetic activity can be determined, even when a very small amount of the reactance tags is present. There-fore, each test will usually require only a droplet of body fluid and the test area can be very small. Consequently, a large number of discrete test areas and if desired, re~erence areas, can be arrayed on a single card or tape.
The discrete areas may be either a series of tests for different select proteins or a series of tests for the same protein where the concentration of immune reagent on the test surface is varied over a range to give an indication of not only the presence of the select protein but also its approx-imate concentration in the body fluid.
The receptor reagent can be attached to the test ~0 surface by surface adsorption, gel entrapment, covalent bonding or other similar methods. Of these, covalent bond-ing is preferred. Any system of receptor attacnment capa~le of orienting the reange molecules on the tes~ surface so that they will have maximum activity is also preferred.
Receptor reagents include not only antibodies, but also tissue or cellular receptor proteins, serum transport pro-teins and lectins. Of these, antibodies probably haYe the widest applicability. Other classes of compounds, such as chelating agents, may also ser~e as useful receptor reagents if they react with the substance to be determined in the S`~3 body fluid with sufficient specificity to avoid false results caused by competing reactions.
The materials useful as reactance tags which combine with immune compounds to form the immune reagents are those which will alter the electrical reactance of the test surface. That is, these materials, if distributed as a finely divided powder on the test surface, alter the dielectric, conductive or the magnetic properties of the surface. The advantage of this invention resides in using particles which are detectable in very small quantities by very sensitive but well developed and readily available electrical components. Further, the use of such materials avoids the problems of transient activity and handling hazards which one encounters in the use of radioactive tags.
The preferred materials are metals and metal oxides. The more preferred metals and metal oxides are those which exhibit ferromagnetism. Such materials can be reacted with the antibodies and applied to the test surace while in a demagneti~ed s-tate. Once they have been applied, the entire surface can be exposed to a magnetic field to magnetize the particles for detection purposes. This magnetic activity is then readily detectable by various well-known means such as a standard magnetic tape system or Hall effect detector.
Magnetic materials include, but are not limited to, metals and alloys such as iron powder, nickel, cobalt, CrO2, FERROFLUID* (a ferromagnetic liquid produced by Ferrofluids Corp.), CoO, NiO, Mn203, magnetoplumbites, magnetic iron oxides and ALNICO*, an alloy of aluminum, nickel cobalt and copper. Other us~ful materials are organic charge complexes with the high electrical conductivity such as * denotes trade mark z503 N-methylphenazinum tetracyanoquinodimethane, ~Ce(NO3)6Mg (H2O)~]3-6H2O crystal, Bi2Se3 crystals and tetrahiofulvalene complexes with tetrocyano-p-quinodimethane or K2Pt(CN4)BrO3-H2O and amorphous materials with magnetic properties such as the chalcogenides, e.g., the europium chalcogenides and chalcogenide glass particles.
Preferred magnetic materials are the magnetic oxides of iron,cobalt, nickel, chromium and maganese and oxide coated particles of iron or nic~el.
In order to provide sufficient surface area for bonding the immune compounds, it is pre~erred that the reactance tags have a large surface area, at least 100 m2/gm.
Particles in the range of 0.01 to 50~m in diameter are preferred.
These materials can be bonded to immune compounds by known techniques. The reactance tags can be encapsulated with an organic polymer to which the immune compounds can be bonded, or the surface can be silanized by conventional techniques. Organic compounds can then be attached to the silane linkage. U.S. 3,954,666 teaches polymer encapsulation o~ core materials and U.S. 3,983,299 teaches the use of silane linkages to bond organic compounds to inorganic particles. Techniques for immobilization of en~ymes on magnetic supports which would be equally applicable to antibodies are described in methods in Enzymology, XLIV
pp. 324-326. The manner of attachment of the reactive organic compounds to the reactan~e tags does not form the basis of this invention. Thus, other bonding methods may also be used so long as they do not interfere with the complexing ability of the immune compounds. The immune ~l~2Z,~C~3 compounds are chosen to be speciically reactive with either the receptor reagents or with the complex of the receptor reagent with the body fluid substance to be determined.
Since the method of this invention utilizes electronic rather than visual inspection it is readily adaptable to automated operation. As used herein, the term "automated" is n,ot meant to exclude the possibility that some of the operations may be performed manually. Referring to Figure 1, a preferred test card 1 is shown having several areas 2 on which receptor reagents are bonded. Separate areas having different receptor reagents can be provided or the same receptor reagent can be bonded to each area in different concentrations. The card has a printed test identification 3, as well as a machine readable code 4, which contains the necessary information for automated operation. Optionally, the card can have a space 5, for entering a pati~nt identification code.
Figure 2 shows schematically a test area 2 of a test card of Fig. 1. Receptor reagents lQ are bonded to the test area. Patient body fluid containing the antibodies 11, the presence of which is to be determined is added to each test area. The antibody 11, if present, forms a complex 12 with the receptor reagent. The test area is then exposed to immune reagent 13 comprised of an immune compound 14 bonded to a reactance tag 15~ This i~mune reagent forms complex 16 ~ith the receptor reagent-patient antibody comple~, if present, on the test area.
A preferred system for the practice o~ this invention would include a station for entering the ne&essary test cards for the desired tests. Cards ma~ be entered _ 9 _ ~1225~3 individually or in group as required. The cards are moved automatically to a sample addition station where a droplet of a patient's body fluid is applied to each of the test areas on the card. An automated device may include temperature control and a station for equilibration o~ the ~ody fluid on the test areas for predetermined times. The card is then moved to a station where the immune reagent is applied to each of the test areas. Again, there may be temperature control and equilibration systems incorporated.
Next, excess immune reagent is removed, and the card is then examined for the presence of reactance tags remaining in the test by measuring changes in electrical reactance o the card test areas.
It should be noted that in the particular embodi-ment described the test card is moved through each station.
Other embodiments where each operation is conducted on a card maintained at a single location in an automated or semi-automated device are equally operable.
The method of this in~ention can be applied to the detection of a wide variety of materials including but not limited to antigens and antibodies of viral, bacterial, cellular and human origin in addition to hormones, drug me~abolites and specific proteins. For example, the method is applicable to the detection of human auto-antibodies, e.g, an antithyroglobulin; antigenic proteins such as complement factors, protein hormones, immunoglobu-lins and free light and heavy chains, e.g , th~roxine-binding globulin, and various species of microorganism antigens and antibodies such as hepatitis A and B virus.
Application o~ this approach is primarily dependent on the ~2:~S~

availability of a suitable material to serve as a receptor reagent specifically reactive with the item to be determined.
EX~MPLE 1 In the determination of a human antibody, IgG, a serum sample can be prediluted with a protein buffer solution containing 0.12~ bovine serum albumin and phosphate buffered saline at pH 7.7 + 0.2. Sodium azide, 0.1~, an antimicro-bial agent can be added in the diluent as a preservative.
The diluted patient sample can be quantitatively transferred to a test reaction card. The solid phase support consisting of anti-human IgG covalently bonded to derivatized polyamide sheets is prepared as follows:
Nylon-6 film tlO g) can be suspended in 3N HCl (300 ml~ and stirred at 30C for four hours, removed from the solution and washed exhaustively with water, ethanol and ether. The carboxyl content of a Nylon-6 film hydro-lyzed for four hours is about 30-90 ~MoLes/gm.
The coupling of the antibody to the depolymerized Nylon-6 support can be carried out by carbodiimide activa-tion. The overall reaction involves the condensation~etween the carboxyl group on the support and the amine groups of the antibody. The reaction is carried out in two steps.
One gram of the acid-treated Nylon-6 film is added to a solution of 50 mg of 1-cyclohexyl-3-(2-morpho-linoethyl)-carbodiimide metho-p-toluenesulfate in 10 ml of water. The reaction mixture is adjusted to pH 4-5 with 6N HClr and the reaction allowed to continue at 30C for two-four hours. The film is then removed and washed several times with water to remove the excess carbodiimide.

~L~2Z503 The acti~ated film is then introduced into a solution containing commercially available anti-numan IgG
in concentrations of 1 to 5Q mg protein in 10 ml of water.
After adjusting the solution to pH between 4-5, the reaction is continued for two to four hours at room temperature or overnight at 4C. The reaction solution is then decanted and the film washed with water or buffer.
The test surface can then be equilibrated with the diluted sample for sufficient time to permit antibody binding to o~cur. The first equilibration may typically be about 30 minutes at 32C. The reaction zones can then be washed with the same protein buffer solution and shaken to wash unabsorbed antigen from the surface.
The test reagent`zones can then be immersed in an excess of goat anti-human IgG tagged with magnetic particles.
For equilibration on the card, the immune particles are appropriately diluted in phosphate saline buffer at pH 7.5 + O.5 containing 0.12% bovine serum albumin. After equili-bration, the test reaction suxfaces can be washed witn the BSA phosphate buffer at pH 7.7 + 0.2.
The reaction surfaces are magnetized in a magnetic field and the test card processed through a detector capa-ble of determining the presence of magnetic particles.
E ~LE 2 -This Example demonstrates the determination of antibodies directed against specific antigens.
A serum sample was prediluted with a protein buffer solution containing 0.1~ bovine serum albumin and Tris-(hydroxymethyl)-aminomethane (Tris) buffered at pH6.5 + O.4. Sodium azide, 0.1~, an antimicrobial agent, was added in the diluent as a preservative.

-- 1~ --~z~so~

The diluted sample was quantitatively transferred to a test reaction surface. The solid phase support consist-ing of human serum albumin covalently bonded to derivatized to either polyamide or polymethacrylic acid polymers was prepared as follows:
The overall coupling reaction between albumin and films can involved cross linking bet~een the amino or carboxyl groups of the film and protein. Cross linking can be achieved through the use of a polyfunctional aziri-dine reagent which is highly reactive with materials con-taining active hydrogens.
The films for attachment of the human serum albumin were first suspended in a 1~ solution of X~A poly-functional aziridine ~Cordova Chemical~ Sacramento, California). Following stirring at 27C for thirty minutes, the films were removed from solution and wahsed with dis-tilled water. The washed films were then stirred in a solution containing human serum albumin (lmg~ml) ror twelve hours at 4C. The immobilized albumin film reatent can then be washed repetitively with Tris buffer (pH6.5 + 0.4) at 4C. The washings are continued until no further albumin is released from the film. Representative levels of albumin attachment to the films are set out below:

Film (~g/cm?) Surface Groups Surlyn~ 3.3 Mylar~ ionomer resin polyester (Flame Treated) 7.3 No Surface Groups Polycarbonate Nylon (HCl Treated) 16.0 Activated Surface Groups Ethylene Maleic Anhydride <1.0 ~lZ;25t:~3 The test surface for anti-HSA was equilibrated with the diluted sample for sufficient time to permit anti-HSA binding. The reaction surface was then washed with the same Tris buffer solution (pH7.4 + 0.4) used in Example 1 to remove unattached sample debris from the surface.
The test reasent card was then immersed with excess of goat anti-human serum albumin tagged with magnetic particles. For equilibration, the immune anti-HSA particles were appropriately diluted in a Tris buffer a pH6.5 + 0.5 containing 0.12~ goat serum albumin. After equilibration the test reaction surfaces were washed free of unattached particles with the goat serum albumin Tris buffer.
The magnetic particles remaining on the reaction surface can be magnetized in response to a magnetic signal of known frequency. The test card can then be processed through a detector, capable of detecting the presence of the magnetic particles. The detection of the reactance properties of the test surface can be adided by the instru-ment techniques of phase lock application, phase sensitive ~0 rectification and other standard electronic amplification systems known to those skilled in the art.
As used herein, the phrase "consisting essentially of" is not use~ to exclude tne additional operation steps or elements which do not prevent the advantage of this invention from being realized.

Claims (10)

1. A method for determining the presence of an analyte in a body fluid consisting essentially of a. contacting a surface with said fluid, said surface being coated with receptor reagents specifically reactive with said analyte;
b. contacting the coated surface with immune reagent comprising immune compound speci-fically reactive with the receptor reagents or with a complex of the analyte and receptor reagent, said immune compound being coated on reactance tags which are particles capable of affecting electrical reactance;
c. removing unreacted immune reagent from the surface; and d. measuring the electric reactance of the surface.
2. The method of Claim 1 wherein the reactance tags are magnetically responsive.
3. The method of Claim 1 wherein the reactance tags exhibit strong capacitive reactance.
4. The method of Claim 1 wherein the reactance tags exhibit conductance.
5. The process of Claim 1 wherein the reactance tags consist essentially of particles selected from the group consisting of metals and metal oxides.
6. The method of Claim 5 wherein the particles are selected from the group consisting of the magnetic oxides of iron, cobalt, chromium, nickel and manganese and oxide coated particles of iron and nickel.
7. The method of Claim 1 wherein said receptor reagent is bonded to said surface by adsorption, gel entrapment or covalent bonding.
8. The method of Claim 1 wherein said receptor reagent is covalently bonded to said surface.
9. The method of Claim 1 wherein said surface is attached to machine readable test information.
10. An automated analytical system including a test surface having a receptor reagent bonded thereto, said receptor reagent being specifically reactive with a com-ponent of a body fluid, a station for the application of a body fluid sample to said test surface, means for the application of an immune reagent to the test area, said immune reagent comprising immune compounds specifically reactive with the receptor reagent or with a complex of the receptor reagent with the component of the body fluid, said immune compounds being coated on reactance tags comprising particles which are capable of affecting electrical reac-tance, means for the removal of excess immune reagent, and means for the detection of reactance tags on said test area.
CA315,018A 1977-11-03 1978-10-31 Immunochemical testing using tagged reagents Expired CA1122503A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84821777A 1977-11-03 1977-11-03
US848,217 1977-11-03
US05/942,261 US4219335A (en) 1978-09-18 1978-09-18 Immunochemical testing using tagged reagents
US942,261 1978-09-18

Publications (1)

Publication Number Publication Date
CA1122503A true CA1122503A (en) 1982-04-27

Family

ID=27126757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA315,018A Expired CA1122503A (en) 1977-11-03 1978-10-31 Immunochemical testing using tagged reagents

Country Status (16)

Country Link
JP (1) JPS5912139B2 (en)
AU (1) AU522995B2 (en)
CA (1) CA1122503A (en)
CH (1) CH638052A5 (en)
DE (1) DE2847282A1 (en)
DK (1) DK489678A (en)
FI (1) FI783346A (en)
FR (1) FR2408142A1 (en)
GB (1) GB2008767B (en)
IE (1) IE47482B1 (en)
IL (1) IL55856A (en)
IT (1) IT1101280B (en)
LU (1) LU80471A1 (en)
NL (1) NL7810910A (en)
NO (1) NO151099C (en)
SE (1) SE431257B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2136130B (en) * 1983-02-28 1987-02-11 Theodore Henry Krueger Chemical assay systems and methods
CA1220818A (en) * 1983-05-05 1987-04-21 Hugh A.O. Hill Assay techniques utilising specific binding agents
GB8314523D0 (en) * 1983-05-25 1983-06-29 Lowe C R Diagnostic device
EP0139373A1 (en) * 1983-08-26 1985-05-02 The Regents Of The University Of California Multiple immunoassay system
JPS6055265A (en) * 1983-09-06 1985-03-30 Fujirebio Inc Measuring method of antigen and antibody by using magnetic particle
GB8331514D0 (en) * 1983-11-25 1984-01-04 Janssen Pharmaceutica Nv Visualization method
EP0170446B1 (en) * 1984-07-10 1991-03-06 Serono Diagnostics Limited Methods of assay
FI844027A (en) * 1984-10-12 1986-04-13 Labsystems Oy IMMUNOLOGISKT BESTAEMNINGSFOERFARANDE.
IL77144A (en) * 1984-11-27 1991-04-15 Orgenics Ltd Method and apparatus for performing solid phase immuno-assay on test card in a plurality of samples
LU86239A1 (en) * 1986-01-02 1987-09-03 Sanders Probel Lab METHOD OF DETECTING REAGENT AGENTS AND MEANS FOR IMPLEMENTING THE SAME
US4794089A (en) * 1986-03-25 1988-12-27 Midwest Research Microscopy, Inc. Method for electronic detection of a binding reaction
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5374524A (en) * 1988-05-10 1994-12-20 E. I. Du Pont De Nemours And Company Solution sandwich hybridization, capture and detection of amplified nucleic acids
GB2270976A (en) * 1992-09-18 1994-03-30 Marconi Gec Ltd Immunoassay/separation process using an auxiliary species on a support
JP2003517575A (en) * 1998-09-08 2003-05-27 テイボテク・エヌ・ブイ Rapid screening of analytes
US6544480B1 (en) 1999-10-26 2003-04-08 Tibotec Bvba Device and related method for dispensing small volumes of liquid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479661A (en) * 1972-06-26 1977-07-13 Gen Electric Method and apparatus for detection and purification of proteins and antibodies
GB1500127A (en) * 1973-10-10 1978-02-08 Abbott Lab Reactive matrices
US4020151A (en) * 1976-02-17 1977-04-26 International Diagnostic Technology, Inc. Method for quantitation of antigens or antibodies on a solid surface
IL49685A (en) * 1976-05-31 1978-10-31 Technion Res & Dev Foundation Specific binding assay method for determining the concentration of materials and reagent means therefor
US4087248A (en) * 1976-07-26 1978-05-02 Miles Laughton E Multiple assay machine and method

Also Published As

Publication number Publication date
NO151099C (en) 1985-02-06
JPS5491296A (en) 1979-07-19
NO783691L (en) 1979-05-04
SE7810351L (en) 1979-05-04
IE782168L (en) 1980-03-18
GB2008767B (en) 1982-06-30
CH638052A5 (en) 1983-08-31
IT7829378A0 (en) 1978-11-02
NL7810910A (en) 1979-05-07
FI783346A (en) 1979-05-04
FR2408142B1 (en) 1984-02-17
AU522995B2 (en) 1982-07-08
FR2408142A1 (en) 1979-06-01
AU4128378A (en) 1979-05-17
IT1101280B (en) 1985-09-28
DK489678A (en) 1979-05-04
IE47482B1 (en) 1984-04-04
DE2847282A1 (en) 1979-05-10
SE431257B (en) 1984-01-23
GB2008767A (en) 1979-06-06
IL55856A0 (en) 1979-01-31
NO151099B (en) 1984-10-29
JPS5912139B2 (en) 1984-03-21
LU80471A1 (en) 1979-06-15
IL55856A (en) 1981-11-30

Similar Documents

Publication Publication Date Title
US4219335A (en) Immunochemical testing using tagged reagents
CA1122503A (en) Immunochemical testing using tagged reagents
JP4324212B2 (en) Magnetically assisted binding assay using magnetically responsive reagents
RU2176393C2 (en) Method and compound for detecting analyte presence using magnitorelaxometry techniques
US6294342B1 (en) Magnetically assisted binding assays utilizing a magnetically responsive reagent
Richardson et al. The use of coated paramagnetic particles as a physical label in a magneto-immunoassay
US4067959A (en) Indirect solid surface test for antigens or antibodies
JP4171139B2 (en) Immunoassay method and apparatus using magnetic substance labeling
EP0124352A2 (en) Protected binding assay
JP2002509242A (en) Force discrimination test
EP0082862B1 (en) A method of detecting or determining histamine in histamine containing materials, particularly body fluids and an analytical means for use in such method
JP4197156B2 (en) Method and apparatus for qualitative and quantitative detection of an analyte
JPH11508031A (en) Methods and compounds for detection utilizing remanence and their use
US20020123079A1 (en) Process for detecting or quantifying a biological rreaction using superparamagnetic label
US20030124745A1 (en) Process for detecting or quantifying a biological reaction using superparamagnetic label
US5202269A (en) Method for immunochemical determination of hapten
WO1996005326A1 (en) Method and apparatus for magnetically detecting proteins and nucleic acids
US6258607B1 (en) Indirect agglutination immunoassay and apparatus therefor
JP2005043049A (en) Method for detecting or determining quantitatively biological reaction using superparamagnetic labeling
CA1083036A (en) Indirect solid surface test for antigens or antibodies
MXPA97005543A (en) Processes and compounds for magnetorrelaxometric detection of analytics and its

Legal Events

Date Code Title Description
MKEX Expiry